Patient Derived Xenograft/PDX Models

Global Market Trajectory & Analytics

MCP13873

EXECUTIVE ENGAGEMENTS

POOL

463
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

93
Interactions with Platform & by Email

PARTICIPANTS

19
Unique # Participated

VALIDATIONS

8
Responses Validated*

COMPANIES

38
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

96

PAGES

164

EDITION

7

PRICE

USD 4950

CODE

MCP13873


COMPETITIVE METRICS

COMPANY

D S N T

% *

Champions Oncology, Inc.

Charles River Laboratories International, Inc.

Crown Bioscience, Inc.

Epo Berlin-Buch GmbH

Hera BioLabs

NexusPharma

Oncodesign

Oncomatryx

Pharmatest Services Ltd.

The Jackson Laboratory

*Login to Participate & View Data Stacks
View 38 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Patient Derived Xenograft/PDX Models estimated at US$102.7 Million in the year 2020, is projected to reach a revised size of US$294.7 Million by 2027, growing at aCAGR of 16.3% over the period 2020-2027. Mouse, one of the segments analyzed in the report, is projected to record 15.3% CAGR and reach US$197.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rat segment is readjusted to a revised 18.4% CAGR for the next 7-year period.
The Patient Derived Xenograft/PDX Models market in the U.S. is estimated at US$30.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$51.2 Million by the year 2027 trailing a CAGR of 15.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.5% and 14% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

SELECT PLAYERS

Champions Oncology, Inc.; Charles River Laboratories International, Inc.; Crown Bioscience, Inc.; Epo Berlin-Buch GmbH; Hera BioLabs; Oncodesign; Pharmatest Services Ltd.; The Jackson Laboratory; Urolead SAS; WuXi AppTec; Xentech

SEGMENTS

» Application (Pre-Clinical Drug Development, Basic Cancer Research) » End-Use (Pharma & Biotech, CRO) » Type (Mouse, Rat)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for Mouse by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Mouse by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Rat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Rat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Pharma & Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pharma & Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
Total Companies Profiled: 38

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com